Viatris

VTRS · Nasdaq · United States

Share price · VTRS

$20.28+4.11 (+25.42%) 3M

close as of 2026-11-18 · 24h delayed · vol 13.3M (1.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when VTRS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Nov 2026+5.0%
  2. 6 Aug 2026-7.7%
  3. 7 May 2026+9.0%
  4. 2 Mar 2026+5.2%
  5. 26 Feb 2026-5.2%
  6. 9 Feb 2026+6.7%
  7. 13 Jan 2026+5.4%

Share of unusual movement by asset

For each asset, the share of VTRS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Sotagliflozin (Inpefa) (Inpefa)
events and moves
81%
Pitolisant (Wakix) (Wakix)
events and moves
4shown from 8 days
Revefenacin (Yupelri)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—49%
Sessions with no dated event—50%

Assets

(13 total)
13Total Assets
13Approved
0Phase 3 / Filed
0Phase 1–2 / Early
18Diseases
Quick filter:
Showing 13 of 13 assets
Target & Modality
Approved
5-HT1B/1D receptorSmall molecule
Migraine
Approved
NMDA receptor (glycine site, antagonist)Small molecule
EpilepsyLennox-Gastaut Syndrome
Focal Onset Seizures
Approved
α2δ subunit of voltage-gated calcium channelsSmall molecule
Epilepsy
Approved
Glucocorticoid receptorSmall molecule
Inflammatory Bowel Disease
Ulcerative Colitis
Approved
AminosalicylateSmall molecule
Inflammatory Bowel Disease
Ulcerative Colitis
Approved
AminosalicylateSmall molecule
Inflammatory Bowel Disease
Ulcerative Colitis
Approved
Voltage-gated sodium channelsSmall molecule
Epilepsy
Approved
Histamine H3 receptor (antagonist / inverse agonist)Small molecule
Myotonic Dystrophy Type 1NarcolepsyIdiopathic HypersomniaPrader-Willi Syndrome
Approved
α2δ subunit of voltage-gated calcium channelsSmall molecule
EpilepsyDiabetic Peripheral Neuropathic PainFibromyalgia
Diabetic Peripheral Neuropathy
Revefenacin(Yupelri)
Approved
Muscarinic receptors (antagonist)Small molecule
Chronic Obstructive Pulmonary Disease
sildenafil(Revatio)
Approved
PDE5Small molecule
Pulmonary Arterial Hypertension
Approved
SGLT1/2 (dual)Small molecule
Heart FailureChronic Kidney DiseaseType 1 DiabetesHypertrophic Cardiomyopathy
Approved
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
SchizophreniaBipolar Disorder

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
January 2027 (1)
Sotagliflozin (Inpefa)Phase 3Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
Est. primary completion 2027-01 · NCT06481891 · CT.gov ↗
What to watch
April 2027 (1)
Pitolisant (Wakix)Phase 3Prader-Willi Syndrome
Est. primary completion 2027-04 · NCT06366464 · CT.gov ↗
What to watch
2030 (1)
August 2030 (1)
Pitolisant (Wakix)Phase 3Prader-Willi Syndrome
Est. primary completion 2030-08 · NCT07219485 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

September 2026ApprovalPitolisant (Wakix)Wakix approved in Japan for narcolepsy and OSAS-associated sleepiness
JP, MHLW · Viatris · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$3.7B$232M$1.8B$325M$899M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$3.7B$248M$890M—$382M operating cash flowreport ↗
2026-Q1$3.5B$249M$1.8B—$388M operating cash flowreport ↗
2025-Q3$3.7B$250M$1.0B—$745M operating cash flowreport ↗
2025-Q2$3.6B$219M$568M—$220M operating cash flowreport ↗
2025-Q1$3.2B$222M$756M—$536M operating cash flowreport ↗
2024-Q3$3.7B$198M$1.9B—$827M operating cash flowreport ↗
2024-Q2$3.8B$204M$919M—$379M operating cash flowreport ↗
2024-Q1$3.7B$200M$1.0B—$615M operating cash flowreport ↗
2023-Q3$3.9B$211M$1.3B—$834M operating cash flowreport ↗
2023-Q2$3.9B$208M$631M—$515M operating cash flowreport ↗
2023-Q1$3.7B$183M$511M—$971M operating cash flowreport ↗
2022-Q3$4.1B$175M$650M—$869M operating cash flowreport ↗
2022-Q2$4.1B$163M$669M—$803M operating cash flowreport ↗
2022-Q1$4.2B$142M$757M—$1.1B operating cash flowreport ↗
2021-Q3$4.5B$152M$762M—$1.1B operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$14.3B—$1.3B+ $41M short-term inv.—$2.3B operating cash flowreport ↗

For full-year 2025, Viatris reported net sales of $14,250.4M, down 3.0% YoY, and total revenues of $14,299.9M, down 3% YoY. R&D expense was $965.9M, cash and equivalents stood at $1,348M, and the company recorded a U.S. GAAP net loss of $3,514.9M, including a $2.9B goodwill impairment.

Management guided 2026 total revenues to $14,450–$14,950M, adjusted EBITDA to $4,150–$4,450M, adjusted EPS to $2.33–$2.47, and free cash flow excluding transaction- and restructuring-related costs to $1,950–$2,350M. The company completed its enterprise-wide strategic review, expecting $650M in total cost savings with up to $250M reinvestment over three years and a workforce reduction of up to approximately 10%. It also closed the Biocon Biologics equity sale, launched Inpefa in the UAE, advanced several regulatory submissions including MR-141 and the low-dose estrogen patch, received FDA approval for generic octreotide acetate, and temporarily suspended production at its Nashik, India facility after a February 2026 fire.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$14.7B—$736M+ $38M short-term inv.—$2.3B operating cash flowreport ↗
2023-FY$15.4B—$994M+ $37M short-term inv.—$2.8B operating cash flowreport ↗
2022-FY$16.2B—$1.3B+ $35M short-term inv.—$3.0B operating cash flowreport ↗
2021-FY$17.8B$751M$706M+ $38M short-term inv.—$3.0B operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 2 sales ($1.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-30SIMMONS DAVID S · directorAward / grant (derivative)2,117$17.72$38KForm 4
2026-09-30Groothuis Leo Frans · directorAward / grant (derivative)2,469$17.72$44KForm 4
2026-08-15Enrietti Andrew · See RemarksOption exercise25,134——Form 4
2026-08-15Enrietti Andrew · See RemarksTax withholding10,931$16.23$177KForm 4
2026-08-15Enrietti Andrew · See RemarksOption exercise999——Form 4
2026-08-15Enrietti Andrew · See RemarksTax withholding435$16.23$7KForm 4
2026-08-15Enrietti Andrew · See RemarksOption exercise (derivative)25,134——Form 4
2026-08-15Enrietti Andrew · See RemarksOption exercise (derivative)998.364——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 1,006 reporting institutions held 990.2M shares ($12.1B, 86.4% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.84,359,804$1.1B
2Davis Selected Advisers78,211,191$1.1B
3VANGUARD CAPITAL MANAGEMENT LLC74,716,631$1.0B
4VANGUARD PORTFOLIO MANAGEMENT LLC53,911,237$728.3M
5STATE STREET CORP52,233,699$705.7M
6DIMENSIONAL FUND ADVISORS LP38,310,693$517.5M
7Rubric Capital Management LP33,500,000$452.6M
8GEODE CAPITAL MANAGEMENT, LLC31,846,107$429.5M
9Invesco Ltd.21,968,657$296.8M
10DEERFIELD MANAGEMENT COMPANY, L.P.20,206,170$273.0M
11AMERIPRISE FINANCIAL INC20,014,966$270.4M
12FMR LLC16,588,514$224.1M
13MORGAN STANLEY16,089,939$217.4M
14Bank of New York Mellon Corp14,128,917$190.9M
15GOLDMAN SACHS GROUP INC13,717,622$185.3M